Search

Your search keyword '"Cheng, Phil"' showing total 8 results
Start Over Author "Cheng, Phil" Journal cancer research
8 results on '"Cheng, Phil"'

1. Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma

Author

Ferretti, Lorenza P., primary, Böhi, Flurina, additional, Leslie Pedrioli, Deena M., additional, Cheng, Phil F., additional, Ferrari, Elena, additional, Baumgaertner, Petra, additional, Alvarado-Diaz, Abdiel, additional, Sella, Federica, additional, Cereghetti, Alessandra, additional, Turko, Patrick, additional, Wright, Roni H., additional, De Bock, Katrien, additional, Speiser, Daniel E., additional, Ferrari, Roberto, additional, Levesque, Mitchell P., additional, and Hottiger, Michael O., additional

Published
2023
Full Text
View/download PDF

2. Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression

Author

Saltari, Annalisa, primary, Dzung, Andreas, additional, Quadri, Marika, additional, Tiso, Natascia, additional, Facchinello, Nicola, additional, Hernández-Barranco, Alberto, additional, Garcia-Silva, Susana, additional, Nogués, Laura, additional, Stoffel, Corinne Isabelle, additional, Cheng, Phil F., additional, Turko, Patrick, additional, Eichhoff, Ossia M., additional, Truzzi, Francesca, additional, Marconi, Alessandra, additional, Pincelli, Carlo, additional, Peinado, Héctor, additional, Dummer, Reinhard, additional, and Levesque, Mitchell P., additional

Published
2021
Full Text
View/download PDF

4. Abstract 2161: Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cell exclusion in tumors and resistance to anti-PD-1 treatment

Author

Wischhusen, Jorg, primary, Wistuba-Hamprecht, Kilian, additional, Harter, Patrick N., additional, Cheng, Phil, additional, Martens, Alexander, additional, Gogolla, Falk, additional, Nonomura, Yumi, additional, Romer, Paula, additional, Koch, Sven D., additional, Haake, Markus, additional, Schuberth-Wagner, Christine, additional, Rudiger, Manfred, additional, Leo, Eugen, additional, Mittelbronn, Michael, additional, Levesque, Mitchell P., additional, Hackl, Hubert, additional, Dummer, Reinhard, additional, and Weide, Benjamin, additional

Published
2020
Full Text
View/download PDF

5. The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype

Author

Vandamme, Niels, primary, Denecker, Geertrui, additional, Bruneel, Kenneth, additional, Blancke, Gillian, additional, Akay, Özden, additional, Taminau, Joachim, additional, De Coninck, Jordy, additional, De Smedt, Eva, additional, Skrypek, Nicolas, additional, Van Loocke, Wouter, additional, Wouters, Jasper, additional, Nittner, David, additional, Köhler, Corinna, additional, Darling, Douglas S., additional, Cheng, Phil F., additional, Raaijmakers, Marieke I.G., additional, Levesque, Mitchell P., additional, Mallya, Udupi Girish, additional, Rafferty, Mairin, additional, Balint, Balazs, additional, Gallagher, William M., additional, Brochez, Lieve, additional, Huylebroeck, Danny, additional, Haigh, Jody J., additional, Andries, Vanessa, additional, Rambow, Florian, additional, Van Vlierberghe, Pieter, additional, Goossens, Steven, additional, van den Oord, Joost J., additional, Marine, Jean-Christophe, additional, and Berx, Geert, additional

Published
2020
Full Text
View/download PDF

6. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma

Author

Siliņa, Karīna, primary, Soltermann, Alex, additional, Attar, Farkhondeh Movahedian, additional, Casanova, Ruben, additional, Uckeley, Zina M., additional, Thut, Helen, additional, Wandres, Muriel, additional, Isajevs, Sergejs, additional, Cheng, Phil, additional, Curioni-Fontecedro, Alessandra, additional, Foukas, Periklis, additional, Levesque, Mitchell P., additional, Moch, Holger, additional, Linē, Aija, additional, and van den Broek, Maries, additional

Published
2018
Full Text
View/download PDF

7. Abstract A04: Aging microenvironment modulates melanoma invasion and metastasis

Author

Kaur, Amanpreet, primary, Marchbank, Katie, additional, Dang, Vanessa, additional, O'Connell, Michael, additional, Webster, Marie, additional, Appleton, Jessica, additional, Cheng, Phil, additional, Valiga, Alexander, additional, Morissette, Rachel, additional, McDonnell, Nazli, additional, Ferrucci, Luigi, additional, Kossenkov, Andrew, additional, Meeth, Katrina, additional, Bosenberg, Marcus, additional, Tang, Hsin-Yao, additional, Yin, Xiangfan, additional, Wood, William, additional, Lehrmann, Elin, additional, Becker, Kevin, additional, Flaherty, Keith, additional, Frederick, Dennie, additional, Wargo, Jennifer, additional, Aird, Katherine, additional, Zhang, Rugang, additional, Xu, Xiaowei, additional, Liu, Qin, additional, Speicher, David, additional, and Weeraratna, Ashani, additional

Published
2015
Full Text
View/download PDF

8. ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.

Author

Eichhoff OM, Stoffel CI, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng PF, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan VS, Wenzina J, Aloia A, Saltari A, Dzung A, Krauthammer M, Schreiber SL, Hornemann T, Distel M, Snijder B, Dummer R, and Levesque MP

Subjects
Humans, Reactive Oxygen Species, Proto-Oncogene Proteins B-raf genetics, Protein Kinase Inhibitors therapeutic use, Mitogen-Activated Protein Kinase Kinases genetics, Cell Line, Tumor, Mutation, Membrane Proteins genetics, GTP Phosphohydrolases genetics, Melanoma drug therapy, Melanoma genetics, Melanoma pathology, Skin Neoplasms drug therapy
Abstract

Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of patients due to resistance that arises through genetic, transcriptional, and metabolic adaptation. Identification of targetable vulnerabilities in NRAS-mutated melanoma could help improve patient treatment. Here, we used multiomics analyses to reveal that NRAS-mutated melanoma cells adopt a mesenchymal phenotype with a quiescent metabolic program to resist cellular stress induced by MEK inhibition. The metabolic alterations elevated baseline reactive oxygen species (ROS) levels, leading these cells to become highly sensitive to ROS induction. In vivo xenograft experiments and single-cell RNA sequencing demonstrated that intratumor heterogeneity necessitates the combination of a ROS inducer and a MEK inhibitor to inhibit both tumor growth and metastasis. Ex vivo pharmacoscopy of 62 human metastatic melanomas confirmed that MEK inhibitor-resistant tumors significantly benefited from the combination therapy. Finally, oxidative stress response and translational suppression corresponded with ROS-inducer sensitivity in 486 cancer cell lines, independent of cancer type. These findings link transcriptional plasticity to a metabolic phenotype that can be inhibited by ROS inducers in melanoma and other cancers., Significance: Metabolic reprogramming in drug-resistant NRAS-mutated melanoma cells confers sensitivity to ROS induction, which suppresses tumor growth and metastasis in combination with MAPK pathway inhibitors., (©2023 American Association for Cancer Research.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results